Leveraging Registries: A Next Step In National Post-Market Plan
This article was originally published in The Gray Sheet
Executive Summary
FDA is making a major push as part of its new post-market surveillance strategy to make better use of existing national patient registries, while avoiding imposition of additional mandatory device registries.